Rapport Therapeutics (RAPP) Current Assets (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Current Assets data on file, last reported at $484.7 million in Q1 2026.

• On a quarterly basis, Current Assets rose 66.58% year-over-year to $484.7 million in Q1 2026; TTM through Mar 2026 was $484.7 million, a 66.58% increase from a year earlier, with the FY2025 full-year figure at $498.6 million, up 60.93% from the prior year.
• Current Assets for Q1 2026 stood at $484.7 million, down from $498.6 million in the prior quarter.
• Over the last five years, Current Assets for RAPP reached as high as $520.7 million in Q3 2025 and fell as low as $150.9 million in Q4 2023.
• Historically, Current Assets has averaged $354.7 million across 4 years, with a median of $325.9 million in 2024.
• Across the five-year window, Current Assets jumped 105.34% in 2024 and slipped 20.67% in 2025, its largest moves.
• Year by year, Current Assets stood at $150.9 million in 2023, then surged by 105.34% to $309.8 million in 2024, then jumped by 60.93% to $498.6 million in 2025, then decreased by 2.78% to $484.7 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $484.7 million in Q1 2026, $498.6 million in Q4 2025, and $520.7 million in Q3 2025.